MA35920B1 - Composés destinés au traitement de l'amyotrophie spinale - Google Patents
Composés destinés au traitement de l'amyotrophie spinaleInfo
- Publication number
- MA35920B1 MA35920B1 MA37313A MA37313A MA35920B1 MA 35920 B1 MA35920 B1 MA 35920B1 MA 37313 A MA37313 A MA 37313A MA 37313 A MA37313 A MA 37313A MA 35920 B1 MA35920 B1 MA 35920B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- treatment
- muscular atrophy
- spinal muscular
- spinal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000002320 spinal muscular atrophy Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des composés, des compositions en contenant et leurs utilisations en vue du traitement de l'amyotrophie spinale.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597523P | 2012-02-10 | 2012-02-10 | |
| PCT/US2013/025292 WO2013119916A2 (fr) | 2012-02-10 | 2013-02-08 | Composés destinés au traitement de l'amyotrophie spinale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35920B1 true MA35920B1 (fr) | 2014-12-01 |
Family
ID=48948163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37313A MA35920B1 (fr) | 2012-02-10 | 2014-08-28 | Composés destinés au traitement de l'amyotrophie spinale |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9586955B2 (fr) |
| EP (2) | EP3406252B1 (fr) |
| JP (2) | JP6092897B2 (fr) |
| KR (2) | KR102137087B1 (fr) |
| CN (3) | CN108299314B (fr) |
| AR (1) | AR092794A1 (fr) |
| AU (2) | AU2013216870B2 (fr) |
| BR (1) | BR112014019750B1 (fr) |
| CA (1) | CA2863874C (fr) |
| CL (1) | CL2014002100A1 (fr) |
| CO (1) | CO7061082A2 (fr) |
| CR (1) | CR20140376A (fr) |
| DK (1) | DK2812004T3 (fr) |
| EA (2) | EA037123B1 (fr) |
| EC (1) | ECSP14017269A (fr) |
| ES (1) | ES2697174T3 (fr) |
| HU (1) | HUE039779T2 (fr) |
| IL (2) | IL233959A (fr) |
| MA (1) | MA35920B1 (fr) |
| MX (2) | MX354074B (fr) |
| NZ (1) | NZ628186A (fr) |
| PE (1) | PE20142364A1 (fr) |
| PH (2) | PH12018501711B1 (fr) |
| PL (1) | PL2812004T3 (fr) |
| SG (2) | SG10201609188WA (fr) |
| TR (1) | TR201813877T4 (fr) |
| TW (2) | TWI629274B (fr) |
| UA (1) | UA116981C2 (fr) |
| WO (1) | WO2013119916A2 (fr) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10327940B2 (en) | 2008-11-09 | 2019-06-25 | 3D Systems, Inc. | Spiral brace |
| JP6193881B2 (ja) | 2011-12-30 | 2017-09-06 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| CA2862084C (fr) | 2012-01-26 | 2021-05-11 | Ptc Therapeutics, Inc. | Derives de 1h-isochromen-1-one et leurs compositions pour le traitement de l'amyotrophie spinale |
| ES2697174T3 (es) * | 2012-02-10 | 2019-01-22 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| KR102099997B1 (ko) | 2012-03-01 | 2020-04-13 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
| US9914722B2 (en) | 2012-03-23 | 2018-03-13 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| WO2014102778A2 (fr) * | 2012-12-24 | 2014-07-03 | Ramot At Tel-Aviv University Ltd. | Agents permettant de traiter des maladies génétiques résultant de mutations non-sens et leurs procédés d'identification |
| CN105392790B (zh) * | 2013-08-19 | 2019-04-19 | 豪夫迈·罗氏有限公司 | 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途 |
| WO2015105657A1 (fr) * | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Procédés pour moduler la quantité de transcrits d'arn |
| DK3143025T3 (da) * | 2014-05-15 | 2019-12-09 | Hoffmann La Roche | Forbindelser til behandling af spinal muskelatrofi |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| WO2016040748A1 (fr) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions et procédés de détection d'une protéine smn chez un patient et traitement d'un patient |
| EP3201339A4 (fr) | 2014-10-03 | 2018-09-19 | Cold Spring Harbor Laboratory | Augmentation ciblée de la production de gènes nucléaires |
| ES2879809T3 (es) * | 2014-11-01 | 2021-11-23 | Shanghai Fochon Pharmaceutical Co Ltd | Ciertos inhibidores de proteínas quinasas |
| EP3242763A4 (fr) * | 2015-01-05 | 2018-08-29 | Sikorsky Aircraft Corporation | Amortisseur de vibrations intégré pour structure fabriquée de manière additive et procédé |
| JP6749343B2 (ja) * | 2015-05-20 | 2020-09-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための化合物 |
| US10668171B2 (en) * | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| AU2016334804B2 (en) | 2015-10-09 | 2022-03-31 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| AU2016353961B2 (en) * | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| CN108137601A (zh) * | 2015-11-12 | 2018-06-08 | 豪夫迈·罗氏有限公司 | 用于治疗肌萎缩性侧索硬化症的化合物 |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| KR20220100719A (ko) | 2015-12-10 | 2022-07-15 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 또는 개선을 위한 조성물 |
| WO2017097728A1 (fr) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Dérivés de pipéridine pontés |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| ES2882500T3 (es) | 2015-12-14 | 2021-12-02 | Cold Spring Harbor Laboratory | Oligómeros antisentido para el tratamiento del síndrome de Dravet |
| WO2017186668A1 (fr) | 2016-04-28 | 2017-11-02 | F. Hoffmann-La Roche Ag | Procédé de préparation de 2-pyrazolo[1,5-a]pyrazine-2-ylpyrido[1,2-a]pyrimidine-4-one |
| WO2017218884A1 (fr) | 2016-06-16 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Combinaisons pour la modulation de l'expression de smn |
| CA3043755A1 (fr) * | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc. | Procedes de modulation de l'epissage de l'arn |
| CA3047403A1 (fr) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics, Inc. | Modulateurs des recepteurs nmda et utilisations de ceux-ci |
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| WO2019005993A1 (fr) * | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Méthodes de traitement de la maladie de huntington |
| CA3067591A1 (fr) * | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Procedes de traitement de la maladie de huntington |
| KR102636383B1 (ko) | 2017-08-04 | 2024-02-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| SI3673080T1 (sl) | 2017-08-25 | 2024-03-29 | Stoke Therapeutics, Inc. | Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni |
| KR20200058468A (ko) | 2017-09-22 | 2020-05-27 | 에프. 호프만-라 로슈 아게 | 7-(4,7-다이아자스피로[2.5]옥탄-7-일)-2-(2,8-다이메틸이미다조[1,2-b]피리다진-6-일)피리도[1,2-a]피리미딘-4-온 유도체의 제조 방법 |
| EP3700570B1 (fr) | 2017-10-23 | 2025-01-08 | Stoke Therapeutics, Inc. | Oligomères antisens pour le traitement d'états et de maladies basés sur le déclin d'arnm à médiation non-sens |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| WO2019213525A1 (fr) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Méthodes et compositions pour le traitement d'une maladie de stockage d'ester de cholestéryle |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| CA3105174A1 (fr) * | 2018-06-27 | 2020-01-02 | Reborna Biosciences, Inc. | Agent prophylactique ou therapeutique pour amyotrophie spinale |
| WO2020005882A1 (fr) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Composés hétéroaryles pour le traitement de la maladie de huntington |
| BR112020026534A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
| CA3108519A1 (fr) | 2018-08-03 | 2020-04-30 | Cadent Therapeutics, Inc. | Modulateurs des recepteurs nmda heteroaromatiques et leurs utilisations |
| KR20210042123A (ko) * | 2018-08-07 | 2021-04-16 | 더 칠드런스 호스피탈 오브 필라델피아 | 유전자 발현의 선택적 스플라이싱 조절 및 치료 방법 |
| CN119320388A (zh) | 2019-02-04 | 2025-01-17 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| KR102913697B1 (ko) | 2019-02-05 | 2026-01-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2020163544A1 (fr) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Procédés et compositions pour moduler l'épissage |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| WO2021021775A1 (fr) | 2019-07-31 | 2021-02-04 | Teva Pharmaceuticals International Gmbh | Formes à l'état solide de risdiplam et leurs procédés de préparation |
| CN110540535B (zh) * | 2019-10-23 | 2020-07-31 | 上海再启生物技术有限公司 | 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法 |
| CN111116576A (zh) * | 2019-12-01 | 2020-05-08 | 北京师范大学 | 一种喹嗪酮类化合物及其制备方法 |
| CN115151540A (zh) | 2019-12-02 | 2022-10-04 | 风暴治疗有限公司 | 作为mettl3抑制剂的多杂环化合物 |
| AU2021214076A1 (en) | 2020-01-28 | 2022-08-04 | Protego Biopharma, Inc. | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| US20230340498A1 (en) * | 2020-02-12 | 2023-10-26 | The Children's Hospital Of Philadelphia | Compositions and methods for inducible alternative splicing regulation of gene expression |
| JP2023515618A (ja) | 2020-02-28 | 2023-04-13 | リミックス セラピューティクス インコーポレイテッド | 核酸スプライシングを調節するためのピリダジン誘導体 |
| US20230148184A1 (en) | 2020-02-28 | 2023-05-11 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| PH12022552258A1 (en) | 2020-02-28 | 2023-11-20 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating smn2 |
| US20240226098A1 (en) | 2020-02-28 | 2024-07-11 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| CA3169697A1 (fr) | 2020-02-28 | 2021-09-02 | Dominic Reynolds | Derives de thiophenyle utiles pour moduler l'epissage d'acide nucleique |
| US20230167093A1 (en) | 2020-04-08 | 2023-06-01 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| KR20230004575A (ko) | 2020-04-08 | 2023-01-06 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| EP4175956A1 (fr) | 2020-07-02 | 2023-05-10 | Remix Therapeutics Inc. | Dérivés de 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine et composés y relatifs en tant que modulateurs pour l'épissage d'acides nucléiques et pour le traitement de maladies proliférantes |
| US20240239811A1 (en) | 2020-07-02 | 2024-07-18 | Remix Therapeutics Inc. | 5-(5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the t |
| WO2022070071A1 (fr) * | 2020-09-30 | 2022-04-07 | Janssen Biotech, Inc. | Inhibiteurs de la dihydroorotate déshydrogénase |
| IL305203A (en) | 2021-03-17 | 2023-10-01 | Hoffmann La Roche | New histories of thiazolopyrimidines |
| WO2023009585A2 (fr) | 2021-07-28 | 2023-02-02 | Protego Biopharma, Inc. | Composés stabilisateurs de transthyrétine |
| US20240368163A1 (en) | 2021-08-30 | 2024-11-07 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| CR20240112A (es) | 2021-08-30 | 2024-08-07 | Remix Therapeutics Inc | Compuestos y métodos para modular splicing |
| EP4395890A1 (fr) | 2021-08-30 | 2024-07-10 | Remix Therapeutics Inc. | Composés et procédés de modulation de l'épissage |
| MX2024002554A (es) | 2021-08-30 | 2024-07-02 | Remix Therapeutics Inc | Compuestos y metodos para modular el empalme. |
| EP4395889A1 (fr) | 2021-08-30 | 2024-07-10 | Remix Therapeutics Inc. | Composés et procédés de modulation de l'épissage |
| TW202330552A (zh) | 2021-10-13 | 2023-08-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
| WO2023064880A1 (fr) * | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Composés et procédés de modulation de l'épissage d'acides nucléiques |
| TW202346305A (zh) | 2022-01-05 | 2023-12-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
| US20250092065A1 (en) | 2022-01-05 | 2025-03-20 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2023133229A2 (fr) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Composés et procédés de modulation d'épissage |
| WO2023240236A1 (fr) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale |
| AU2024286618A1 (en) * | 2023-06-09 | 2025-10-30 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
| CN117263936B (zh) * | 2023-11-21 | 2024-02-23 | 中国中医科学院医学实验中心 | 一种咪唑并[1, 2-a]吡啶衍生物及其制备方法和在中枢神经系统渗透性HDAC6抑制药物中的应用 |
| WO2025233837A1 (fr) | 2024-05-07 | 2025-11-13 | Takeda Pharmaceutical Company Limited | Dérivés de 4h-pyrimido[1,2-a]pyrimidin-4-one destinés à être utilisés en tant qu'inhibiteurs de l'inflammasome nlrp3 pour le traitement d'un trouble neurodégénératif |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558618A (en) * | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| JPS56150091A (en) * | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
| AU4231293A (en) * | 1992-05-13 | 1993-12-13 | E.I. Du Pont De Nemours And Company | Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides |
| EP0871628A1 (fr) | 1995-06-06 | 1998-10-21 | Abbott Laboratories | Composes de type quinolizinone |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| US6630488B1 (en) * | 1998-09-21 | 2003-10-07 | Biochem Pharma, Inc. | Quinolizinones as integrin inhibitors |
| CN1414951A (zh) * | 1999-10-28 | 2003-04-30 | 基本治疗公司 | 药剂排出泵抑制药 |
| EP1857443B1 (fr) * | 2000-01-24 | 2012-03-28 | AstraZeneca AB | Composés thérapeutiques morpholino substitués |
| CA2665516A1 (fr) * | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Inhibiteur de pompe d'expulsion de medicaments |
| CA2469316A1 (fr) | 2001-12-07 | 2003-06-19 | Vertex Pharmaceuticals, Inc. | Composes a base de pyrimidine utiles en tant qu'inhibiteurs des gsk-3 |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| EP1542667B1 (fr) | 2002-07-24 | 2012-03-07 | PTC Therapeutics, Inc. | Composes d'acide benzoique a substitution ureido et leur utilisation pour la suppression de non-sens et le traitement de maladie |
| EP1636225B1 (fr) * | 2003-06-20 | 2010-02-24 | Novartis Vaccines and Diagnostics, Inc. | Composes de pyridino 1,2-a pyrimidin-4-one servant d'agents anticancereux |
| DE602005002562T2 (de) * | 2004-05-04 | 2008-01-31 | Warner-Lambert Company Llc | Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel |
| AU2006206446A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| WO2009151546A2 (fr) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Procédés de traitement d'une atrophie musculaire spinale |
| EP2138493A1 (fr) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Dérivés substitués de pyrimidone |
| US8986935B2 (en) | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2011050245A1 (fr) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Hétéroaryles bicycliques formant inhibiteurs de la kinase |
| WO2011062853A1 (fr) * | 2009-11-20 | 2011-05-26 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 de type quinolizidinone-carboxamide |
| AU2011206761A1 (en) * | 2010-01-13 | 2012-07-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti - infective pyrido (1,2 -a) pyrimidines |
| JP6193881B2 (ja) | 2011-12-30 | 2017-09-06 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| CA2862084C (fr) | 2012-01-26 | 2021-05-11 | Ptc Therapeutics, Inc. | Derives de 1h-isochromen-1-one et leurs compositions pour le traitement de l'amyotrophie spinale |
| ES2697174T3 (es) * | 2012-02-10 | 2019-01-22 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| KR102099997B1 (ko) | 2012-03-01 | 2020-04-13 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
| US9914722B2 (en) | 2012-03-23 | 2018-03-13 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| DK3143025T3 (da) | 2014-05-15 | 2019-12-09 | Hoffmann La Roche | Forbindelser til behandling af spinal muskelatrofi |
| JP6749343B2 (ja) | 2015-05-20 | 2020-09-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための化合物 |
-
2013
- 2013-02-08 ES ES13747100T patent/ES2697174T3/es active Active
- 2013-02-08 PE PE2014001250A patent/PE20142364A1/es active IP Right Grant
- 2013-02-08 UA UAA201409921A patent/UA116981C2/uk unknown
- 2013-02-08 CN CN201810234432.7A patent/CN108299314B/zh active Active
- 2013-02-08 NZ NZ628186A patent/NZ628186A/en unknown
- 2013-02-08 CN CN201380019368.6A patent/CN104349777B/zh active Active
- 2013-02-08 HU HUE13747100A patent/HUE039779T2/hu unknown
- 2013-02-08 MX MX2014009696A patent/MX354074B/es active IP Right Grant
- 2013-02-08 EP EP18179491.8A patent/EP3406252B1/fr active Active
- 2013-02-08 SG SG10201609188WA patent/SG10201609188WA/en unknown
- 2013-02-08 KR KR1020147025275A patent/KR102137087B1/ko active Active
- 2013-02-08 BR BR112014019750-4A patent/BR112014019750B1/pt active IP Right Grant
- 2013-02-08 CN CN202411603136.1A patent/CN119528903A/zh active Pending
- 2013-02-08 CA CA2863874A patent/CA2863874C/fr active Active
- 2013-02-08 KR KR1020207020788A patent/KR102341596B1/ko active Active
- 2013-02-08 US US14/377,531 patent/US9586955B2/en active Active
- 2013-02-08 JP JP2014556711A patent/JP6092897B2/ja active Active
- 2013-02-08 EA EA201792465A patent/EA037123B1/ru unknown
- 2013-02-08 SG SG11201404713PA patent/SG11201404713PA/en unknown
- 2013-02-08 DK DK13747100.9T patent/DK2812004T3/en active
- 2013-02-08 WO PCT/US2013/025292 patent/WO2013119916A2/fr not_active Ceased
- 2013-02-08 TR TR2018/13877T patent/TR201813877T4/tr unknown
- 2013-02-08 AU AU2013216870A patent/AU2013216870B2/en active Active
- 2013-02-08 PH PH1/2018/501711A patent/PH12018501711B1/en unknown
- 2013-02-08 EA EA201491505A patent/EA029542B1/ru not_active IP Right Cessation
- 2013-02-08 EP EP13747100.9A patent/EP2812004B1/fr active Active
- 2013-02-08 PL PL13747100T patent/PL2812004T3/pl unknown
- 2013-02-14 AR ARP130100450 patent/AR092794A1/es active IP Right Grant
- 2013-02-18 TW TW106106161A patent/TWI629274B/zh active
- 2013-02-18 TW TW102105672A patent/TWI585085B/zh active
-
2014
- 2014-08-05 IL IL233959A patent/IL233959A/en active IP Right Grant
- 2014-08-07 PH PH12014501786A patent/PH12014501786B1/en unknown
- 2014-08-08 CL CL2014002100A patent/CL2014002100A1/es unknown
- 2014-08-08 CR CR20140376A patent/CR20140376A/es unknown
- 2014-08-11 MX MX2022011699A patent/MX2022011699A/es unknown
- 2014-08-28 MA MA37313A patent/MA35920B1/fr unknown
- 2014-09-04 EC ECIEPI201417269A patent/ECSP14017269A/es unknown
- 2014-09-09 CO CO14198817A patent/CO7061082A2/es unknown
-
2016
- 2016-08-26 US US15/248,052 patent/US9879007B2/en active Active
-
2017
- 2017-02-09 JP JP2017022640A patent/JP6363744B2/ja active Active
- 2017-06-22 AU AU2017204248A patent/AU2017204248B2/en active Active
- 2017-08-17 IL IL254045A patent/IL254045B/en active IP Right Grant
- 2017-12-20 US US15/848,075 patent/US20180105526A1/en not_active Abandoned
-
2019
- 2019-08-15 US US16/541,401 patent/US10851101B2/en active Active
-
2020
- 2020-10-05 US US17/062,853 patent/US11753407B2/en active Active
-
2023
- 2023-07-26 US US18/359,209 patent/US20240067646A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491412A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| GEP20166438B (en) | Imidazopyrrolidinone compounds | |
| MA39193B1 (fr) | Modulateurs du gpr6 à base de tétrahydropyridopyrazines | |
| EA201491505A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| MA46490A1 (fr) | Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués | |
| MA38143A1 (fr) | Composition comprenant des agents de lutte biologique | |
| MA48577A1 (fr) | Composes biheteroaryle et leurs utilisations | |
| EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
| EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
| MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
| EA201390274A1 (ru) | Борсодержащие малые молекулы | |
| MX362655B (es) | Composiciones cosmeticas. | |
| EA201201374A1 (ru) | Лечение атаксии-телеангиэктазии | |
| EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
| EA201100505A1 (ru) | Органические соединения для применения для лечения бактериальных инфекций | |
| EA201492002A1 (ru) | Противовирусные соединения | |
| EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
| EA201491854A1 (ru) | Асимметрический синтез соединений спирооксиндола, полезных в качестве терапевтических средств | |
| FR3012725B1 (fr) | Compositions d'agents de lutte biologique, leur procede de preparation et leurs utilisations | |
| MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MA39152A1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| MX342924B (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
| MX2014004858A (es) | Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas. |